ATE403736T1 - Onkolytische adenovirale vektoren - Google Patents

Onkolytische adenovirale vektoren

Info

Publication number
ATE403736T1
ATE403736T1 AT02714960T AT02714960T ATE403736T1 AT E403736 T1 ATE403736 T1 AT E403736T1 AT 02714960 T AT02714960 T AT 02714960T AT 02714960 T AT02714960 T AT 02714960T AT E403736 T1 ATE403736 T1 AT E403736T1
Authority
AT
Austria
Prior art keywords
adenoviral vectors
adenoviral
nucleic acid
viral vector
oncolytic adenoviral
Prior art date
Application number
AT02714960T
Other languages
English (en)
Inventor
David Ennist
Suzanne Forry-Schaudies
Mario Gorziglia
Paul Hallen-Beck
Carl Hay
John Jakubczak
Michael Kaleko
Patricia Ryan
David Stewart
Yuefeng Xie
Sheila Connelly
Seshidhar Reddy Police
Lori Clarke
Sandrina Phipps
Cheng Cheng
Original Assignee
Cell Genesys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cell Genesys Inc filed Critical Cell Genesys Inc
Application granted granted Critical
Publication of ATE403736T1 publication Critical patent/ATE403736T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/007—Vector systems having a special element relevant for transcription cell cycle specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT02714960T 2001-02-23 2002-02-22 Onkolytische adenovirale vektoren ATE403736T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27092201P 2001-02-23 2001-02-23
US29503701P 2001-06-01 2001-06-01
US34867002P 2002-01-14 2002-01-14

Publications (1)

Publication Number Publication Date
ATE403736T1 true ATE403736T1 (de) 2008-08-15

Family

ID=27402327

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02714960T ATE403736T1 (de) 2001-02-23 2002-02-22 Onkolytische adenovirale vektoren

Country Status (8)

Country Link
US (1) US20030104625A1 (de)
EP (1) EP1377671B1 (de)
JP (1) JP2004529627A (de)
AT (1) ATE403736T1 (de)
CA (1) CA2439115A1 (de)
DE (1) DE60228066D1 (de)
IL (1) IL152420A0 (de)
WO (1) WO2002067861A2 (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5998205A (en) * 1994-11-28 1999-12-07 Genetic Therapy, Inc. Vectors for tissue-specific replication
US6492343B1 (en) * 1998-04-15 2002-12-10 University Of Saskatchewan Porcine adenovirus type 3 genome
US6900049B2 (en) * 1998-09-10 2005-05-31 Cell Genesys, Inc. Adenovirus vectors containing cell status-specific response elements and methods of use thereof
US20030143200A1 (en) * 2001-09-24 2003-07-31 Tikoo Suresh K. Porcine adenovirus E1 region
US7569217B2 (en) * 2001-09-24 2009-08-04 University Of Saskatchewan Porcine adenovirus E1 and E4 regions
EP1496979A4 (de) * 2002-03-22 2007-10-31 Univ Texas Protamin-adenovirale vektor-komplexe und anwendungsverfahren
JP3867968B2 (ja) * 2002-07-08 2007-01-17 関西ティー・エル・オー株式会社 腫瘍細胞において選択的に増殖する腫瘍融解ウイルス
US8163892B2 (en) * 2002-07-08 2012-04-24 Oncolys Biopharma, Inc. Oncolytic virus replicating selectively in tumor cells
US7364727B2 (en) 2002-07-22 2008-04-29 Cell Genesys, Inc. Metastatic colon cancer specific promoter and uses thereof
US7371570B2 (en) 2002-11-01 2008-05-13 Cell Genesys, Inc. Cell-specific adenovirus vector comprising EBV-specific promoter
AU2002352007A1 (en) * 2002-11-14 2004-06-03 Medizinische Hochschule Hannover Agents and methods for detecting human adenoviruses
US20070275915A1 (en) * 2003-04-15 2007-11-29 Cell Genesys, Inc. Tmprss2 Regulatory Sequences and Uses Thereof
US20050136035A1 (en) * 2003-06-03 2005-06-23 Derek Ko Cell specific replication-competent viral vectors comprising a self processing peptide cleavage site
US7498024B2 (en) * 2003-06-03 2009-03-03 Cell Genesys, Inc. Compositions and methods for enhanced expression of immunoglobulins from a single vector using a peptide cleavage site
WO2005030261A1 (en) * 2003-08-28 2005-04-07 Cell Genesys, Inc. Oncolytic adenoviral vectors encoding gm-csf
US20050186178A1 (en) * 2003-08-28 2005-08-25 Ennist David L. Oncolytic adenoviral vectors encoding GM-CSF
US7482156B2 (en) * 2003-10-15 2009-01-27 Cell Genesys, Inc. Hepatocellular carcinoma specific promoter and uses thereof
US20050097066A1 (en) * 2003-10-31 2005-05-05 Pitney Bowes Incorporated Method and system for a mailing machine to verify the integrity of printed postage
DE602005015332D1 (de) 2004-02-23 2009-08-20 Crucell Holland Bv Verfahren zur Reinigung von Viren
US7473418B2 (en) 2004-03-25 2009-01-06 Cell Genesys, Inc. Pan cancer oncolytic vectors and methods of use thereof
EP1765362B1 (de) * 2004-06-04 2012-03-28 The Scripps Research Institute Zusammensetzungen und verfahren zur behandlung von neovaskulären erkrankungen
CN100361710C (zh) * 2004-06-07 2008-01-16 成都康弘生物科技有限公司 肿瘤细胞专一表达免疫调节因子gm-csf的溶瘤性腺病毒重组体的构建及其应用
US20060062764A1 (en) * 2004-08-25 2006-03-23 Seshidar-Reddy Police Fiber-modified adenoviral vectors for enhanced transduction of tumor cells
ES2317517T5 (es) 2005-04-11 2016-01-21 Crucell Holland B.V. Purificación de virus usando ultrafiltración
KR100756055B1 (ko) * 2006-01-27 2007-09-07 연세대학교 산학협력단 신생혈관 생성을 조절하는 재조합 아데노바이러스
CN100488568C (zh) * 2006-04-03 2009-05-20 南京师范大学 一种能分泌内皮抑素的细胞制剂及其在制备治疗肿瘤的药中的应用
US20100316609A1 (en) * 2006-10-18 2010-12-16 University Of Rochester Conditionally Replicating Viruses for Cancer Therapy
EP1947463A1 (de) * 2007-01-16 2008-07-23 Roche Diagnostics GmbH Entnahme von flüssigen Analyseproben zum Zweck der klinischen Analyse
CN102448487B (zh) 2009-03-16 2016-03-16 麦克马斯特大学 疫苗接种方法
ES2385251B1 (es) 2009-05-06 2013-05-06 Fundació Privada Institut D'investigació Biomèdica De Bellvitge Adenovirus oncolíticos para el tratamiento del cáncer.
BR112012012160B1 (pt) 2009-11-13 2022-04-26 Amgen, Inc. Material e métodos para tratar ou prevenir doenças associadas ao her-3
WO2012000188A1 (en) * 2010-06-30 2012-01-05 Tot Shanghai Rd Center Co., Ltd. Recombinant tumor vaccine and method of producing such
CA2815154A1 (en) 2010-08-06 2012-02-09 U3 Pharma Gmbh Use of her3 binding agents in prostate treatment
FI123955B (en) 2011-11-25 2014-01-15 Oncos Therapeutics Ltd Oncolytic adenovirus
WO2013119880A1 (en) 2012-02-07 2013-08-15 Global Bio Therapeutics Usa, Inc. Compartmentalized method of nucleic acid delivery and compositions and uses thereof
US20140350087A9 (en) 2012-03-22 2014-11-27 Halozyme, Inc. Oncovector Nucleic Acid Molecules and Methods of Use
CN105658790A (zh) 2013-02-21 2016-06-08 东安大略研究所儿童医院有限公司 疫苗组合物
JP6576326B2 (ja) 2013-03-14 2019-09-18 ソーク インスティテュート フォー バイオロジカル スタディーズ 腫瘍溶解性アデノウイルス組成物
CN103555765B (zh) * 2013-05-30 2015-01-07 中南大学湘雅医院 一种转录调控肿瘤靶向复制溶瘤腺病毒载体、携带治疗基因腺病毒及其制备方法和应用
CN105813579B (zh) 2013-08-08 2019-05-07 全球生物疗法有限公司 用于微创手术过程的夹具装置和其应用
US20180369417A1 (en) * 2015-09-01 2018-12-27 Industry-University Coorperation Foundation Hanyang University Antitumor immunity enhancing composition containing adenovirus simultaneously expressing il-12 and shvegf
US10626413B2 (en) 2016-01-15 2020-04-21 Enyu Ding Nucleic acid vector
AU2017223589B2 (en) 2016-02-23 2023-08-03 Salk Institute For Biological Studies Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics
CA3013637A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
WO2018111767A1 (en) 2016-12-12 2018-06-21 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof
CA3225845A1 (en) * 2017-03-25 2018-10-04 Gen-Probe Incorporated Methods and compositions to detect combinations of viral nucleic acids
KR102702230B1 (ko) * 2017-05-26 2024-09-03 에피센트알엑스, 인코포레이티드 트랜스진을 보유하는 재조합 아데노바이러스
WO2019048689A1 (en) 2017-09-11 2019-03-14 Imba - Institut Für Molekulare Biotechnologie Gmbh TUMOR ORGANOID MODEL
EP3733854A4 (de) * 2017-12-28 2021-12-01 Bionoxx Inc. Onkolytisches virus mit verbesserter sicherheit und antikrebswirkung
WO2021031551A1 (zh) * 2019-08-19 2021-02-25 南京诺惟生物科技有限公司 一种调控脂质代谢的复制型溶瘤腺病毒及其应用
EP4340855A1 (de) 2021-08-13 2024-03-27 Triovance Holding LLC Hautersatzzusammensetzung und verfahren zur herstellung und verwendung davon
CN117568405B (zh) * 2023-11-14 2024-06-14 武汉凯德维斯生物技术有限公司 一种溶瘤腺病毒重组载体、构建方法及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5998205A (en) * 1994-11-28 1999-12-07 Genetic Therapy, Inc. Vectors for tissue-specific replication
US5880102A (en) * 1995-01-17 1999-03-09 Duke University Adenoviral vector system
FR2763958A1 (fr) * 1997-05-29 1998-12-04 Transgene Sa Produit de combinaison associant un acide nucleique a une substance desorganisant la matrice extracellulaire pour la therapie genique
US6214620B1 (en) * 1998-09-29 2001-04-10 The Johns Hopkins University Inducible genetic suppression of cellular excitability
WO2000031286A1 (en) * 1998-11-20 2000-06-02 Valentis, Inc. Adenoviral vector-mediated delivery of modified steroid hormone receptors and related products and methods
US6420345B1 (en) * 1999-03-01 2002-07-16 Cell Genesys, Inc. Methods and reagents for inhibiting angiogenesis
US7396679B2 (en) * 1999-11-15 2008-07-08 Onyx Pharmaceuticals, Inc. Oncolytic adenovirus

Also Published As

Publication number Publication date
IL152420A0 (en) 2003-05-29
WO2002067861A3 (en) 2003-08-21
DE60228066D1 (de) 2008-09-18
EP1377671B1 (de) 2008-08-06
EP1377671A2 (de) 2004-01-07
CA2439115A1 (en) 2002-09-06
WO2002067861A2 (en) 2002-09-06
JP2004529627A (ja) 2004-09-30
US20030104625A1 (en) 2003-06-05

Similar Documents

Publication Publication Date Title
ATE403736T1 (de) Onkolytische adenovirale vektoren
Ward et al. Stringent chemical and thermal regulation of recombinant gene expression by vaccinia virus vectors in mammalian cells.
AU696495B2 (en) Adenoviral vectors of animal origin and use in gene therapy
EP0753068B1 (de) Adenovirusfaser mit hinzugefügten liganden
US10316065B2 (en) Oncolytic adenoviruses for treating cancer
ATE332965T1 (de) Komplementierende zellinien
JP2020010684A5 (de)
CA2229631A1 (en) Gene therapy using ovine adenoviral vectors
DE69638196D1 (de) Rekombinantes sendai-virus
WO2005005610A3 (en) Mutant adeno-associated virus virions and methods of use thereof
ES2170622A1 (es) Clones y vectores infectivos derivados de coronavirus y sus aplicaciones.
IS4754A (is) Genaferjur og aðferðir fyrir genaflutning inn í frumur
DE69739870D1 (de) Verbesserte adenovirusvektoren
WO2001027304A3 (en) Lentiviral triplex dna, and vectors and recombinant cells containing lentiviral triplex dna
WO2000073478A3 (en) Recombinant adenoviral vectors expressing chimeric fiber proteins for cell specific infection and genome integration
Pearce et al. Glycoviruses: chemical glycosylation retargets adenoviral gene transfer
US20030175244A1 (en) Capsid-modified recombinant adenovirus and methods of use
EP2044950A3 (de) Abgeschwächte Vif-DNA-Immunisierungskassetten für genetische Impfstoffe
Duffy et al. Generation and characterization of a novel candidate gene therapy and vaccination vector based on human species D adenovirus type 56
WO2004018627A3 (en) Methods for propagating adenovirus and virus produced thereby
WO2003029433A3 (en) Chimeric viral vectors for gene therapy
WO2001044458A3 (en) Bovine immunodeficiency virus (biv) based vectors
Li et al. Adenovirus fiber shaft contains a trimerization element that supports peptide fusion for targeted gene delivery
Cai et al. Organization of the avian adenovirus genome and the structure of its endopeptidase
WO2002008436A3 (en) Mini-adenoviral vector system for vaccination

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties